Medicover ABLTS:0RPS +0.42%89 EBITDA Margin % is 15.97% as of Mar. 2026, which is 10% above its 10-year median of 14.50. GuruFocus rates LTS:0RPS with a GF Score™ of 89/100 and a GF Value™ of kr233.91 (Fairly Valued). The stock has 5 warning signs investors should review. Among 666 Healthcare Providers & Services companies, Medicover AB ranks better than 64.26% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medicover AB's EBITDA for the
three
months ended in Mar. 2026 was kr1,074 Mil. Medicover AB's Revenue for the
three
months ended in Mar. 2026 was kr6,723 Mil. Therefore, Medicover AB's EBITDA margin for the quarter that ended in Mar. 2026 was 15.97%.
Medicover AB (LTS:0RPS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medicover AB EBITDA Margin % Related Terms
Medicover AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medicover AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RPS vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Medicover AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicover AB EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medicover AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medicover AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicover AB (LTS:0RPS) has a EBITDA Margin % of 15.97% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medicover AB and its competitors. This is 10% above median its historical median of 14.50. Over the past decade, Medicover AB's EBITDA Margin % has ranged from 8.08 to 19.96. According to the industry distribution chart, Medicover AB ranks #238 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 35.7%.
Is Medicover AB's EBITDA Margin % too high?
Medicover AB's current EBITDA Margin % of 15.97% is 10% above median its 10-year median of 14.50. Over the past 10 years, this metric has ranged from a low of 8.08 to a high of 19.96. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Medicover AB's value of 15.97% is 56.4% above this industry median. Based on the distribution chart, Medicover AB ranks #238 out of 666 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Medicover AB has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medicover AB's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Medicover AB ranks #238 out of 666 companies for EBITDA Margin %. This puts Medicover AB in the upper half of its industry. The industry median EBITDA Margin % is 10.21. Medicover AB's value of 15.97% is 56.4% above this benchmark. Historically, Medicover AB's own EBITDA Margin % has ranged from 8.08 to 19.96 over the past decade. While the company's 10-year median is 14.50 vs. the industry median of 10.21, Medicover AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicover AB's current EBITDA Margin % of 15.97% is 56.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medicover AB and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicover AB's current EBITDA Margin % is 15.97%, which is 10% above median its own 10-year median of 14.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicover AB stock overvalued right now?
Based on GuruFocus' analysis, Medicover AB (LTS:0RPS) is currently considered Fairly Valued. The stock's GF Value™ is kr233.91, compared to a current price of kr238.00 — trading 1.7% above its estimated fair value. The current EBITDA Margin % is 15.97%, which is 10% above median its 10-year median of 14.50 and 56.4% above the Healthcare Providers & Services industry median of 10.21. Medicover AB's overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medicover AB (LTS:0RPS), the current EBITDA Margin % is 15.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicover AB (LTS:0RPS) Overvalued in 2026?
Based on GuruFocus' analysis, Medicover AB stock appears to be overvalued.
The current stock price of kr238.00 is trading 1.7% above its estimated GF Value™ of kr233.91.
GuruFocus considers Medicover AB to be Fairly Valued.
Key valuation signals for LTS:0RPS:
EBITDA Margin %: 15.97% (10% above median its 10-year median of 14.50)
GF Value™: kr233.91 vs. price of kr238.00 (1.7% above fair value)
Industry Position: 56.4% above the Healthcare Providers & Services median (#238 of 666)
No single metric tells the full story. See the LTS:0RPS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicover AB is an international healthcare and diagnostic services provider. It offers a broad spectrum of healthcare services via an extensive network of ambulatory clinics, hospitals, specialty-care facilities, and laboratories. Medicover offers its services through two reportable segments: Healthcare Services, which generates the maximum revenue, and Diagnostic Services. Diagnostic Services offer a broad range of laboratory testing in all clinical pathology areas, and Healthcare Services offer medical care and related services by operating on an Integrated Healthcare and Fee-For-Service model across different countries. Geographically, the company derives maximum revenue from Germany, and the rest from Poland, India, Ukraine, Romania, and other countries.
89GF Score
Get the complete analysis for LTS:0RPS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RPS has been successfully added to your 
